Department of Developmental Biology, Department of Bioengineering, and McGowan Institute of Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Stem Cells Transl Med. 2014 Feb;3(2):183-93. doi: 10.5966/sctm.2013-0122. Epub 2013 Dec 26.
Valuable and ample resources have been spent over the last two decades in pursuit of interventional strategies to treat the unmet demand of heart failure patients to restore myocardial structure and function. At present, it is clear that full restoration of myocardial structure and function is outside our reach from both clinical and basic research studies, but it may be achievable with a combination of ongoing research, creativity, and perseverance. Since the 1990s, skeletal myoblasts have been extensively investigated for cardiac cell therapy of congestive heart failure. Whereas the Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial revealed that transplanted skeletal myoblasts did not integrate into the host myocardium and also did not transdifferentiate into cardiomyocytes despite some beneficial effects on recipient myocardial function, recent studies suggest that skeletal muscle-derived stem cells have the ability to adopt a cardiomyocyte phenotype in vitro and in vivo. This brief review endeavors to summarize the importance of skeletal muscle stem cells and how they can play a key role to surpass current results in the future and enhance the efficacious implementation of regenerative cell therapy for heart failure.
在过去的二十年中,人们投入了宝贵而丰富的资源来寻求介入策略,以满足心力衰竭患者对恢复心肌结构和功能的未满足需求。目前,从临床和基础研究来看,完全恢复心肌结构和功能显然是无法实现的,但结合正在进行的研究、创造力和毅力,这可能是可以实现的。自 20 世纪 90 年代以来,骨骼肌成肌细胞已被广泛研究用于充血性心力衰竭的心脏细胞治疗。虽然肌母细胞自体移植治疗缺血性心肌病(MAGIC)试验表明,尽管对受者心肌功能有一些有益影响,但移植的骨骼肌成肌细胞并未整合到宿主心肌中,也没有转分化为心肌细胞,但最近的研究表明,骨骼肌来源的干细胞具有在体外和体内采用心肌细胞表型的能力。这篇简短的综述旨在总结骨骼肌干细胞的重要性,以及它们如何在未来发挥关键作用,超越当前的结果,并增强心力衰竭再生细胞治疗的有效实施。